

Provider Bulletin January 2022

Pharmacy billing guidance: COVID-19 vaccine additional doses for immunocompromised individuals

Highmark Blue Cross Blue Shield of Western New York partners with Amerigroup companies to administer certain services to Medicaid Managed Care (MMC) and Child Health Plus (CHPlus) members. Please note, this information is specific to the MMC and CHPlus programs only.

On August 13, 2021, the Advisory Committee on Immunization Practices (ACIP) met and recommended an additional dose for immunocompromised individuals who received the Pfizer-BioNTech or Moderna COVID-19 vaccine.

For all plans covering COVID-19 vaccine administration under the pharmacy benefit, providers must submit additional dose claims for immunocompromised individuals with a submission clarification code (SCC) (National Council for Prescription Drug Programs [NCPDP] field 42Ø-DK) value of **Ø7**.

Per the emergency use authorization (EUA), the additional dose for immunocompromised individuals should be administered at least 28 days following the first two doses of the vaccine.

When submitting claims for additional COVID-19 vaccine doses, the provider must document how the eligible individual meets the criteria. This may be in the form of an attestation from the eligible individual (which should be noted by the pharmacist when the attestation is received verbally) or documentation of the eligible individual's qualifying condition or therapy in an accessible paper or electronic record. All documentation to support the administration of an additional dose must be retrievable for audit purposes.

Amerigroup Partnership Plan, LLC provides management services for Highmark Blue Cross Blue Shield of Western New York's managed Medicaid. Amerigroup Partnership Plan, LLC brinda servicios administrativos para Medicaid administrado de Highmark Blue Cross Blue Shield of Western New York